Stockhouse: Taking Unparalleled Results to Treat the Next Epidemic
Since donning its new corporate identity earlier this year, Algernon Pharmaceuticals Inc. (CSE: AGN, OTCQB: BTHCF, Forum) has been busy advancing its research and its business. Much like the classic novel the clinical stage Company derived its name from, which built its theme around change, Algernon is shifting to become a phase II clinical trial Company. Having changed its name to Algernon in February 2019, the corporate shift was intended to align its operation with its main strategy to be a global leader in the treatment of liver disease, non-alcoholic steatohepatitis (NASH), chronic kidney disease (CKD) and inflammatory bowel disease (IBD). NASH is a common liver …
About Us
Get the skills, guidance, and resources you need to make a big difference in your contact center operations that can lead to a big difference